NCT05673889View on ClinicalTrials.gov

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 27, 2023

Primary Completion Date

March 15, 2023

Study Completion Date

April 19, 2023

Conditions
Healthy
Interventions
DRUG

ARV-471

Experimental

DRUG

Dabigatran etexilate

Probe substrate

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY